Barreras de acceso a la telemedicina en tiempos de COVID-19, un desafío profesional y gubernamental

Dear editor: The pandemic caused by SARS-CoV-2 (COVID-19) infection isolated the world for months and impacted morbidity and mortality rate figures. 215,047,649 cases and 4,480,486 deaths have been reported worldwide as of August 27, 2021. In Colombia, 4,899,085 cases and 124,567 deaths were reported as of the same date (1). Mandatory isolation was among the health measures to reduce propagation. This situation drove all sectors to transform. With respect to the health care system, telemedicine (TM) was quickly implemented as one of its strategies. The term TM was introduced in 1970 as “healing at a distance,” defined by the World Health Organization as “The delivery of health care services using information and communication technologies for diagnosis, treatment and prevention of disease” (2). The objectives of TM are to improve the quality of health care services, reduce transportation costs, reduce wait times and provide more opportunities to attend to geographically distant areas. In addition to the above, it allowed decreasing patients and health care professionals’ exposure to the infection in pandemic context (3,4).Estimada Editora: La pandemia secundaria a la infección por SARS-CoV-2 (COVID-19) aisló durante meses al mundo y produjo un impacto en las cifras de morbilidad y mortalidad. Al 27 de agosto de 2021 se han reportado a nivel mundial 215,047,649 casos y 4,480,486 muertes. En Colombia, para la misma fecha se reportaron 4,899,085 casos y 124,567 muertes (1). Entre las medidas sanitarias para disminuir la propagación de la infección se implementó el aislamiento obligatorio, condición que impulsó a todos los sectores a generar transformaciones. Para el caso del sistema de salud, entre sus estrategias se generó una rápida implementación de la telemedicina (TM). El término TM se introdujo en 1970 como la “curación a distancia”, definida por la Organización Mundial de la Salud como “la prestación de servicios de atención médica mediante el uso de tecnologías de la información y la comunicación para realizar un diagnóstico, tratamiento y prevención de enfermedades” (2). Los objetivos de la TM son mejorar la calidad del servicio de salud, reducción de los costos de transporte, disminución de los tiempos de espera para la atención y brindar mayor oportunidad de atención a zonas geográficas distantes. Sumado a lo anterior, en el contexto de la pandemia permitió disminuir la exposición a la infección en los pacientes y profesionales en salud (3,4)

Comparison of 1-year outcome in patients with severe aorta stenosis treated conservatively or by aortic valve replacement or by percutaneous transcatheter aortic valve implantation (data from a multicenter Spanish registry)

The factors that influence decision making in severe aortic stenosis (AS) are unknown. Our aim was to assess, in patients with severe AS, the determinants of management and prognosis in a multicenter registry that enrolled all consecutive adults with severe AS during a 1-month period. One-year follow-up was obtained in all patients and included vital status and aortic valve intervention (aortic valve replacement [AVR] and transcatheter aortic valve implantation [TAVI]). A total of 726 patients were included, mean age was 77.3 ± 10.6 years, and 377 were women (51.8%). The most common management was conservative therapy in 468 (64.5%) followed by AVR in 199 (27.4%) and TAVI in 59 (8.1%). The strongest association with aortic valve intervention was patient management in a tertiary hospital with cardiac surgery (odds ratio 2.7, 95% confidence interval 1.8 to 4.1, p <0.001). The 2 main reasons to choose conservative management were the absence of significant symptoms (136% to 29.1%) and the presence of co-morbidity (128% to 27.4%). During 1-year follow-up, 132 patients died (18.2%). The main causes of death were heart failure (60% to 45.5%) and noncardiac diseases (46% to 34.9%). One-year survival for patients treated conservatively, with TAVI, and with AVR was 76.3%, 94.9%, and 92.5%, respectively, p <0.001. One-year survival of patients treated conservatively in the absence of significant symptoms was 97.1%. In conclusion, most patients with severe AS are treated conservatively. The outcome in asymptomatic patients managed conservatively was acceptable. Management in tertiary hospitals is associated with valve intervention. One-year survival was similar with both interventional strategies

Memorias IX Congreso Geológico Venezolano (4)

Memorias IX Congreso Geol&oacute;gico Venezolano (4

New insights into the genetic etiology of Alzheimer’s disease and related dementias

Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/‘proxy’ AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele

New insights into the genetic etiology of Alzheimer’s disease and related dementias

Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/‘proxy’ AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele

ESICM LIVES 2016: part two : Milan, Italy. 1-5 October 2016.

Meeting abstrac